循环肿瘤细胞表达与经奥希替尼联合EP化疗治疗的晚期NSCLC患者生存的相关性  

Correlation Between the Expression of Circulating Tumor Cells and the Survival of Patients with Advanced Non-small Cell Lung Cancer Treated with Osimertinib Combined with EP Chemotherapy

作　　者：李文见 LI Wenjian(Department of Oncology,Central Hospital of Shangqiu,Shangqiu 476000,China)

机构地区：[1]商丘市中心医院肿瘤科,河南商丘476000

出　　处：《河南医学研究》2023年第6期1068-1071,共4页Henan Medical Research

摘　　要：目的分析循环肿瘤细胞(CTCs)表达与奥希替尼联合EP化疗治疗晚期非小细胞肺癌(NSCLC)患者生存的相关性,寻找晚期非小细胞肺癌化疗患者生存预测指标。方法本研究采用前瞻性分析方法,纳入商丘市中心医院2019年9月至2021年9月医院收治的81例晚期NSCLC患者。全部患者均接受奥希替尼联合EP化疗治疗,随访1 a,末次随访时间截止至2022年9月,记录患者总生存期(OS),观察生存情况。记录患者一般资料和相关实验室指标,检测血清CTCs表达。重点分析CTCs表达与奥希替尼联合EP化疗治疗晚期NSCLC患者生存的相关性。结果纳入的75例晚期NSCLC患者中,有30例死亡,死亡率为40.00%;死亡组的血清NSE、CEA和CTCs水平均高于存活组(P<0.05);两组性别、年龄等一般资料和其他实验室指标比较,差异无统计学意义(P>0.05);经点二列相关性检验,NSE、CEA、CTCs与晚期NSCLC患者死亡呈正相关性(r>0,P<0.05);CTCs高表达组的生存时间短于CTCs低表达组(P<0.05)。结论血清CTCs表达与奥希替尼联合EP化疗治疗晚期NSCLC患者生存情况存在一定的关系,当血清CTCs表达越高,死亡风险越高,或可作为预测晚期NSCLC患者生存的辅助指标之一。Objective To analyze the correlation between the expression of circulating tumor cells(CTCs)and the survival of patients with advanced non-small cell lung cancer(NSCLC)treated with osimertinib combined with EP chemotherapy,and to find the prognostic indicators for the survival of patients with advanced non-small cell lung cancer treated with chemotherapy.Methods A prospective analysis method was adopted in this study,including 81 patients with advanced NSCLC admitted to Central Hospital of Shangqiu from September 2019 to September 2021.All patients received osimertinib combined with EP chemotherapy,and were followed up for 1 year.The last follow-up time was until September 2022.The overall survival(OS)of patients were recorded,and the survival was observed.The general data of patients and related laboratory indexes were recorded,and the expression of serum CTCs was detected.The correlation between the expression of CTCs and the survival of patients with advanced NSCLC treated with osimertinib combined with EP chemotherapy was analyzed.Results Among 75 patients with advanced NSCLC,30 patients died,with a fatality rate of 40.00%.The levels of serum NSE,CEA and CTCs in the dead group were higher than those in the surviving group(P<0.05).There was no statistical significant difference between the two groups in terms of gender,age and other general data and other laboratory indicators(P>0.05).The point binary correlation test showed that NSE,CEA,CTCs were positively correlated with the mortality of patients with advanced NSCLC(r>0,P<0.05).The survival time of high expression group of CTCs was shorter than that of low expression group of CTCs(P<0.05).Conclusion There is a certain relationship between the expression of serum CTCs and the survival of patients with advanced NSCLC treated with osimertinib combined with EP chemotherapy.When the expression of serum CTCs is higher,the risk of death is higher,or it can be used as one of the auxiliary indicators to predict the survival of patients with advanced NSCLC.

关 键 词：非小细胞肺癌 奥希替尼 化疗 生存 循环肿瘤细胞 

分 类 号：R734.2[医药卫生—肿瘤]